(Q43781411)

English

Continuation of a randomized, double-blind, multicenter study of linezolid versus vancomycin in the treatment of patients with nosocomial pneumonia

scientific article published in March 2003

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

Continuation of a randomized, double-blind, multicenter study of linezolid versus vancomycin in the treatment of patients with nosocomial pneumonia (English)

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Sue K Cammarata

object named as

Sue K Cammarata

2

0 references

Richard G. Wunderink

object named as

Richard G Wunderink

1

0 references

4

object named as

Marin H Kollef

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

author name string

Thomas H Oliphant

3

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

Linezolid Nosocomial Pneumonia Study Group

5

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

publication date

1 March 2003

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

Clinical Therapeutics

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

25

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

3

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

980-992

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

Nosocomial infections in combined medical-surgical intensive care units in the United States

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980118-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Mortality due to ventilator-associated pneumonia or colonization with Pseudomonas or Acinetobacter species: assessment by quantitative culture of samples obtained by a protected specimen brush

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980118-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Hospital-acquired pneumonia: methicillin resistance and intensive care unit admission

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980118-2

7 January 2021

based on heuristic

inferred from DOI database lookup

The oxazolidinone linezolid inhibits initiation of protein synthesis in bacteria

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980118-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Mechanism of action and in vitro and in vivo activities of S-6123, a new oxazolidinone compound

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980118-2

7 January 2021

based on heuristic

inferred from DOI database lookup

In vitro activities in new oxazolidinone antimicrobial agents against enterococci

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980118-2

7 January 2021

based on heuristic

inferred from DOI database lookup

In vitro activities of linezolid against important gram-positive bacterial pathogens including vancomycin-resistant enterococci

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980118-2

7 January 2021

based on heuristic

inferred from DOI database lookup

In vitro activities of U-100592 and U-100766, novel oxazolidinone antibacterial agents

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980118-2

7 January 2021

based on heuristic

inferred from DOI database lookup

In vivo activities of U-100592 and U-100766, novel oxazolidinone antimicrobial agents, against experimental bacterial infections.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980118-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: a randomized, double-blind, multicenter study

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980118-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Linezolid-induced pure red blood cell aplasia

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980118-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Hematologic effects of antimicrobials: focus on the oxazolidinone linezolid

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980118-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Thrombocytopenia associated with linezolid therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980118-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Serum Vancomycin Concentrations: Reappraisal of Their Clinical Value

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980118-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Monitoring serum vancomycin levels: climbing the mountain because it is there?

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980118-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Outcome assessment of minimizing vancomycin monitoring and dosing adjustments

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980118-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Vancomycin therapeutic drug monitoring: is there a consensus view? The results of a UK National External Quality Assessment Scheme (UK NEQAS) for Antibiotic Assays questionnaire

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980118-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Treatment of gram-positive nosocomial pneumonia. Prospective randomized comparison of quinupristin/dalfopristin versus vancomycin. Nosocomial Pneumonia Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980118-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Antimicrobial action and pharmacokinetics/pharmacodynamics: the use of AUIC to improve efficacy and avoid resistance.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980118-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0149-2918(03)80118-2

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43781411&oldid=2103277719"